Abstract
Despite the advances in neonatal intensive care, bronchopulmonary dysplasia (BPD) still remains a major cause of mortality and morbidity in many preterm infants. A definitive treatment still does not exist, and BPD has serious consequences, including poor cardiopulmonary function and development. Hence, to address this need, a randomized clinical trial (NCT03041740) is currently underway to assess the safety and feasibility of partial liquid ventilation (PLV) in preterm infants with severe BPD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have